News: Companies

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors
05:10pSANUWAVE HEALTH, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
AQ
05:10pPMV PHARMACEUTICALS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
05:10pBLACKROCK TCP CAPITAL CORP. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
05:10pESPERION THERAPEUTICS, INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)
AQ
05:10pNORTHWEST NATURAL HOLDING CO : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
05:10pOnconova Therapeutics Announces Abstract at the ASCO Annual Meeting Highlighting Narazaciclib's Differentiated Inhibitory and Improved Safety Profile in Preclinical Models
AQ
05:10pAadi Bioscience Announces Exploratory Biomarker Data from Patients in Its AMPECT Trial and Expanded Access Program to be Presented at 2022 ASCO Annual Meeting
AQ
05:09pENJOY TECHNOLOGY, INC./DE : Change in Directors or Principal Officers (form 8-K)
AQ
05:09pEx-Virginia Tech linebacker testifies in fatal beating trial
AQ
05:09pADAMIS PHARMACEUTICALS CORP : Change in Directors or Principal Officers, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
05:09pCANOPY GROWTH CORP : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
05:08pLSI INDUSTRIES INC : Change in Directors or Principal Officers (form 8-K)
AQ
05:08pMETAL SKY STAR ACQUISITION CORP : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
05:07pMEDTECH ACQUISITION CORP : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits (form 8-K)
AQ
05:07pINTERNATIONAL TOWER HILL MINES LTD : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
Discover
05:07pBentley Systems, Incorporated Declares Second Quarter 2022 Dividend
BU
05:07pVeracyte Announces New Data to be Presented at ASCO 2022 Showing Immunoscore IC Assay's Ability to Identify Patients with NSCLC Who May Benefit from Immune Checkpoint Inhibitors
BU
05:06pBEYOND MEAT, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
05:06pSilvercorp reports adjusted earnings of $52.4 million, $0.30 per share, and cash flow from operations of $107.4 million for fiscal 2022
AQ
05:06pF&M BANK CORP : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
05:06pPMV Pharmaceuticals Announces Initial PC14586 Phase 1 Clinical Data to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
AQ
05:06pFanhua Announces Distribution of CNFinance Shares
AQ
05:06pAffimed Highlights Trial Designs of Three AFM24 Ongoing Clinical Studies at the Annual Meeting of the American Society of Clinical Oncology (ASCO)
AQ
05:06pArbutus Announces Abstract Selected for Publication at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
GL
05:06pPuma Biotechnology Announces Publication of Abstracts on Neratinib for the 2022 ASCO Annual Meeting
BU
05:06pMereo BioPharma Announces the Presentation of Updated Data From a Phase 1b/2 Study of Etigilimab as a Poster at the 2022 American Society of Clinical Oncology Annual Meeting
GL
05:06pXencor Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb®104, PD-1 x ICOS Bispecific Antibody, in Advanced Solid Tumors
BU
05:06pMereo BioPharma Announces the Presentation of Updated Data From a Phase 1b/2 Study of Etigilimab as a Poster at the 2022 American Society of Clinical Oncology Annual Meeting
GL
05:05pArbutus Announces Abstract Selected for Publication at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
AQ
05:05pExelixis Announces Detailed Results from Urothelial Carcinoma and Non-Small Cell Lung Cancer Cohorts of the COSMIC-021 Trial at ASCO 2022
BU
05:05pMEI Pharma and Kyowa Kirin Announce Acceptance of Abstract for Presentation at the American Society of Clinical Oncology Annual Meeting 2022
BU
05:04pLUFF ENTERPRISES Announces First Quarter Financial Results and Provides Corporate Update
AQ
05:04pNN INC : Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)
AQ
05:04pORASURE TECHNOLOGIES INC : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)
AQ
05:04pCPI CARD GROUP INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
05:04pPCB BANCORP : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
05:04pTARONIS FUELS, INC. : Regulation FD Disclosure (form 8-K)
AQ
05:04pINVESTCORP INDIA ACQUISITION CORP : Other Events (form 8-K)
AQ
05:04pSplunk Ranks First in both IT Markets and Security Markets in Gartner® Market Share Report
BU
05:04pMomelotinib Pivotal Phase 3 Data Receives Oral Presentation at American Society of Clinical Oncology Annual Meeting
BU
05:04pImmunoGen Presents Additional Efficacy and Safety Analyses Evaluating Mirvetuximab Soravtansine in Ovarian Cancer at ASCO
BU
05:04pClinical Data Demonstrating Promising Antitumor Activity with Zanidatamab in 1L Setting of HER2‑Positive Breast and Gastroesophageal Cancers to be Presented at ASCO 2022
BU
05:04pAdicet Bio Reports Positive Clinical Update from ADI-001 Phase 1 Trial in Relapsed/Refractory Non-Hodgkin's Lymphoma (NHL)
BU
05:04pPrairie Provident Reports on AGM Voting Results
GL
05:04pPrairie Provident Reports on AGM Voting Results
GL
05:04pExelixis Announces Results from Phase 2 Trial of Cabozantinib in Combination with Pembrolizumab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma at ASCO 2022
BU
05:03pBicycle Therapeutics to Present Trials in Progress Poster Featuring BT7480 Phase I/II Clinical Trial at the 2022 ASCO Annual Meeting
BU
05:03pSpectrum Pharmaceuticals to Present Data at 2022 ASCO Highlighting the Potential Predictive Capabilities of ctDNA as a Biomarker for Poziotinib Treatment Response
BU
05:03pDYCOM INDUSTRIES INC : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
05:02pNew Pivotal Data Demonstrate Clinical Benefit of Genentech's Glofitamab, a Potential First-in-Class Bispecific Antibody for People With Aggressive Lymphoma
BU
05:02pVolatus Aerospace Corp. Announces Record First Quarter Annual Sales
AQ
05:02pDIME COMMUNITY BANCSHARES, INC. /NY/ : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
05:02pElectra Makes Steady Progress in Q1 2022 Towards Commissioning its Cobalt Refinery
AQ
05:02pPDS Biotech Announces Presentation of Efficacy and Safety Data from VERSATILE-002 Phase 2 Clinical Trial in Recurrent or Metastatic Head and Neck Cancer at ASCO 2022
AQ
05:02pUniversity of Iowa Holden Comprehensive Cancer Center Presents Preliminary Data from Clinical Trial of Vidutolimod at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
GL
05:02pJust Energy Announces Stay Extension and Adjournment of Motions for Meetings Order and Authorization Order
GL
05:02pGalane Gold Ltd. Releases Financial and Operating Results for Q1
GL
05:02pEQRx Announces New Data for Lead Oncology Programs in Non-small Cell Lung Cancer and Rare Form of Non-Hodgkin Lymphoma at ASCO 2022
GL
05:02pData from Phase 2 PILOT Study of Bristol Myers Squibb's CAR T cell Therapy Breyanzi Show Substantial Durable Responses in Patients with Refractory or Relapsed Large B-cell Lymphoma After First-Line Therapy
BU
05:01pCAVCO : Fiscal Q4 Earnings Snapshot
AQ
Prev.1  2  3   4  5  6  7  8  9  10Next